| Literature DB >> 32271599 |
Ali Motlagh1,2, Maisa Yamrali3, Samira Azghandi4, Payam Azadeh2, Mohammad Vaezi4, Farzaneh Ashrafi5, Kazem Zendehdel6, Hamidreza Mirzaei2, Ali Basi7, Afshin Rakhsha2, Sharareh Seifi8, Morteza Tabatabaeefar2, Ahmad Elahi9, Pouneh Pirjani10, Leila Moadab Shoar3, Faranak Nadarkhani11, Mostafa Khoshabi12, Massih Bahar13, Fatemeh Esfahani8,14, Hossein Fudazi15, Farhad Samiei16,17, Borna Farazmand18, Azin Ahmari19, Mojtaba Vand Rajabpour6, Ghasem Janbabaei4,20, Alireza Raisi21,22, Afshin Ostovar1,23, Reza Malekzadeh1,24,25.
Abstract
On March 11th 2020, the coronavirus outbreak was declared a pandemic by the WHO. One of the groups that is considered high risk in this pandemic are cancer patients as they are treated with a variety of immune system suppressor treatment modalities and this puts them in a great risk for infectious disease (including COVID-19). Therefore, cancer patients require higher level measures for preventing and treating infectious diseases. furthermore, cancer patients may bear additional risk due to the restriction of access to the routine diagnostic and therapeutic services during such epidemic. Since most of the attention of health systems is towards patients affected with COVID-19, the need for structured and unified approaches to COVID-19 prevention and care specific to cancer patients and cancer centers is felt more than ever. This article provides the recommendations and possible actions that should be considered by patients, their caregivers and families, physician, nurses, managers and staff of medical centers involved in cancer diagnosis and treatment. We pursued two major goals in our recommendations: first, limiting the exposure of cancer patients to medical environments and second, modifying the treatment modalities in a manner that reduces the probability of myelosuppression such as delaying elective diagnostic and therapeutic services, shortening the treatment course, or prolonging the interval between treatment courses.Entities:
Keywords: COVID-19; Cancer; Pandemic
Mesh:
Year: 2020 PMID: 32271599 DOI: 10.34172/aim.2020.07
Source DB: PubMed Journal: Arch Iran Med ISSN: 1029-2977 Impact factor: 1.354